Document detail
ID

doi:10.1007/s40618-024-02352-z...

Author
Schubert, L. Mbekwe-Yepnang, A. M. Wassermann, J. Braik-Djellas, Y. Jaffrelot, L. Pani, F. Deniziaut, G. Lussey-Lepoutre, C. Chereau, N. Leenhardt, L. Bernier, M- O. Buffet, C.
Langue
en
Editor

Springer

Category

Medicine & Public Health

Year

2024

listing date

4/10/2024

Keywords
risk factors differentiated thyroid carcinoma radioiodine refractory thyroid car... distant metastases prediction score thyroid dtc predicting risk
Metrics

Abstract

Purpose Risk factors for developing radioiodine refractory thyroid cancer (RAIR-TC) have rarely been analyzed.

The purpose of the present study was to find clinical and pathological features associated with the occurrence of RAIR-disease in differentiated thyroid cancers (DTC) and to establish an effective predictive risk score.

Methods All cases of RAIR-DTC treated in our center from 1990 to 2020 were retrospectively reviewed.

Each case was matched randomly with at least four RAI-avid DTC control patients based on histological and clinical criteria.

Conditional logistic regression was used to examine the association between RAIR-disease and variables with univariate and multivariate analyses.

A risk score was then developed from the multivariate conditional logistic regression model to predict the risk of refractory disease occurrence.

The optimal cut-off value for predicting the occurrence of RAIR-TC was assessed by receiver operating characteristic (ROC) curves and Youden’s statistic.

Results We analyzed 159 RAIR-TC cases for a total of 759 controls and found 7 independent risk factors for predicting RAIR-TC occurrence: age at diagnosis ≥ 55, vascular invasion, synchronous cervical, pulmonary and bone metastases at initial work-up, cervical and pulmonary recurrence during follow-up.

The predictive score of RAIR-disease showed a high discrimination power with a cut-off value of 8.9 out of 10 providing 86% sensitivity and 92% specificity with an area under the curve (AUC) of 0.95.

Conclusion Predicting the occurrence of RAIR-disease in DTC patients may allow clinicians to focus on systemic redifferentiating strategies and/or local treatments for metastatic lesions rather than pursuing with ineffective RAI-therapies.

Schubert, L.,Mbekwe-Yepnang, A. M.,Wassermann, J.,Braik-Djellas, Y.,Jaffrelot, L.,Pani, F.,Deniziaut, G.,Lussey-Lepoutre, C.,Chereau, N.,Leenhardt, L.,Bernier, M- O.,Buffet, C., 2024, Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status, Springer

Document

Open

Share

Source

Articles recommended by ES/IODE AI